Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

Viewpoints_Christophe Piketty
Fingers Crossed: Christophe Piketty from Galderma in a Stimulating Conversation with PharmaShots
Shots:  Atopic dermatitis remains one of the most common inflammatory skin diseases, affecting more than 230M people across the globe. Characterized by frequent itching and recurrent skin lesions, atopic dermatitis is a chronic condition  Recently the Lancet published data from Galderma’s P-III trial, ARCADIA 1 and ARCADIA 2, demonstrating the potential of nemolizumab to improve skin…
September 11, 2024
Viewpoints_Piotr Trzonkowski
Enhancing Care: Piotr Trzonkowski from PolTREG in an Interesting Dialogue Exchange with PharmaShots
Shots:   Recently, PolTREG announced positive long-term follow-up data for PTG-007 from the P-I/II studies for early-onset type 1 diabetes  PolTREG develops therapies using T-regulatory cells for autoimmune diseases. With the positive results, PolTREG has met EMA’s requirement to confirm the safety of Treg therapies at least five years after the administration  Today, at PharmaShots, we…
September 4, 2024
Viewpoints_Kasper Roet 
Advancing Neurodegenerative Care: Kasper Roet from QurAlis Corporation in a Stimulating Conversation with PharmaShots
Shots:  Recently, QurAlis signed an exclusive license agreement with Lilly for QRL-204 for patients with ALS and FTD  Under the terms of the agreement, QurAlis granted Lilly an exclusive worldwide license to develop and commercialize QRL-204 and other UNC13A targeting compounds.  QurAlis received an up front payment of $45M plus an additional equity investment. The company is…
September 2, 2024
Viewpoints_Regina Fritsche-Danielson
AstraZeneca at ERA 2024: Regina Fritsche-Danielson in an Illuminating Dialogue Exchange with PharmaShots
Shots:  Associated with early onset and rapid progression of chronic kidney disease (CKD), APOL1 Mediated Kidney Disease dramatically affects people of African descent  AstraZeneca is developing AZD2373, the first potential precision treatment option for the treatment of AMKD with Ionis Pharmaceuticals. Recently, AZ shared promising data from the early P-I data from the MAD study …
August 26, 2024
Viewpoints_Manojkumar Bupathy
Advancing Cancer Therapy Delivery: Manojkumar Bupathy from Rocky Mountain Cancer Centers in Conversation with PharmaShots
Shots:  Addressing a high unmet medical need, PharmaShots had a riveting dialogue exchange with Manojkumar Bupathy from Rocky Mountain Cancer Centers  Manojkumar shared insights from the real-world study that analysed the treatment pattern and clinical outcomes in patients with locally advanced/metastatic urothelial carcinoma   The study reveals that four out of the ten patients received only…
August 20, 2024
Viewpoints_Jennifer Fernandez
TCOC Management in Oncology: Jennifer Fernandez from The Oncology Network in a Dialogue Exchange with PharmaShots
Shots:  Prominent oncology drugs like pembrolizumab and nivolumab were initially approved with weight-based dosing and gradually transitioned to fixed dozing. With the transformation in the dosing model, the average dose amount administered to patients increased dramatically in the Oncology Care Model  Today, at PharmaShots, we have Jennifer Fernandez from The Oncology Network, shedding light on…
August 7, 2024
Load more